In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eloxx Pharmaceuticals Ltd.

www.eloxxpharma.com

Latest From Eloxx Pharmaceuticals Ltd.

Finance Watch: Investors Bet On Hope As Four Early-Stage Companies Launch US IPOs

Public Company Edition: Of five drug developers expected to go public, four have preclinical or early clinical candidates, while the one that could not find a market for its IPO is in Phase III. Also, Biohaven, Zymeworks and Kura raise $100m or more in follow-on offerings.

Financing Business Strategies

Early Stage Candidates Carving Out New Routes In Cystic Fibrosis

Scrip spoke to two companies from a fresh wave of innovators that are approaching drug development for cystic fibrosis from a new angle.

Respiratory Research and Development Strategies

Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer

Public Company Edition: Strategies diverge in obesity as Vivus restructures debt and raises cash for a new deal and new focus, after Orexigen nears a sale of the company via bankruptcy court. Also, Clovis leads recent offerings, while layoffs are on the table at Catabasis.

Financing Business Strategies

Spotlight On Israel: Accessing Private Cash For Novel Technologies

Israel's appetite for biopharma investment is growing, but competition for cash is still tough and local investors are not only looking at regional startups to place their bets on.

Israel Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Eloxx Pharmaceuticals Ltd.
  • Senior Management
  • Robert Ward, Chmn. & CEO
    Gregory Weaver, CFO
    Pedro Huertas, MD, PhD, CMO
    David P Snow, CBO
  • Contact Info
  • Eloxx Pharmaceuticals Ltd.
    Phone: 8-8505664
    10 Prof. Menachem Plaut St.
    Rehovot, 7670621
    Israel
UsernamePublicRestriction

Register